Genmab AS Sees Significant Drop in Short Interest
| GMAB Stock | USD 19.35 0.12 0.62% |
About 62% of Genmab AS's investor base is looking to short. The analysis of overall sentiment of trading Genmab AS stock suggests that many investors are alarmed at this time. The current market sentiment, together with Genmab AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Genmab AS stock news signals to limit their universe of possible portfolio assets.
Genmab |
Genmab AS was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 2,020,000 shares, a decline of 11.4 percent from the November 15th total of 2,280,000 shares. Based on an average daily volume of 1,150,000 shares, the short-interest ratio is
Read at thelincolnianonline.com
 |
Genmab AS Fundamental Analysis
We analyze Genmab AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Genmab AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Genmab AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Genmab AS is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Genmab AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Genmab AS stock to make a market-neutral strategy. Peer analysis of Genmab AS could also be used in its relative valuation, which is a method of valuing Genmab AS by comparing valuation metrics with similar companies.
Peers
Genmab AS Related Equities
| TERN | Terns Pharmaceuticals | 3.10 | ||||
| TVTX | Travere Therapeutics | 3.06 | ||||
| DAWN | Day One | 2.37 | ||||
| AMLX | Amylyx Pharmaceuticals | 1.63 | ||||
| PCVX | Vaxcyte | 0.36 | ||||
| APLS | Apellis Pharmaceuticals | 0.56 | ||||
| BPMC | Blueprint Medicines | 0.68 | ||||
| ALEC | Alector | 2.72 | ||||
| ASND | Ascendis Pharma | 3.39 | ||||
| LEGN | Legend Biotech | 4.40 | ||||
| EWTX | Edgewise Therapeutics | 4.46 | ||||
| AKRO | Akero Therapeutics | 4.53 | ||||
| CYTK | Cytokinetics | 8.41 |
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |